Replies to post #188 on Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

GSK is transferring back the NY-ESO-1 and PRAME programs. This was due to a ''strategic review'' following lete-cel data in NSCLC.

In 2014, the two signed a collaboration and license agreement, for up to five programs. In 2017, GSK exercised its option to exclusively license the right to develop and commercialise NY-ESO-1, after which two more targets, including PRAME, were nominated.

Adaptimmune said it is expected that that the license agreement will now terminate, and GSK will not have any rights to nominate any additional targets. The terms of the transfer are being negotiated; the company added. Adaptimmune noted that GSK will deliver data from an ongoing PhII (registration-directed) trial with lete-cel in STS with final data expected in 2023.

Adaptimmune said it will continue to prioritise and focus on its lead MAGE-A4 franchise while deciding an optimal development path for the other assets.